Acorda Therapeutics, Inc. has entered a partnership with Biopas Laboratories to commercialize INBRIJA in Latin America, a press release reported.
“We are excited to be collaborating with Acorda to make INBRIJA available to people with Parkinson’s disease in Latin America,” CEO of Biopas, Pascal Forget, said in a release. “This important partnership supports Biopas’ mission to cover unmet medical needs of patients from Argentina to Mexico. INBRIJA further strengthens Biopas’ complete and innovative CNS portfolio now consisting of nine original treatments: For Parkinson’s disease, epilepsy, movement disorders, sialorrea, multiple sclerosis, anxiety and sleep disorders.”
According to the press release, the health prescription medication treats episodic motor fluctuations (OFF episodes) in adult patients living with Parkinson's disease (PD) using a levodopa/dopa-decarboxylase inhibitor.
Under the terms of the distribution and supply agreement, Acorda will receive double the sale price of INBRIJA in Latin America in exchange for supply of the product, and Biopas will retain exclusive distribution rights to the product in nine countries within Latin America, including Brazil and Mexico.
According to recent population-related projections, a minimum of 400,000 people suffer from Parkinson's disease in the region. The brand currently awaits marketing authorization to broaden local accessibility.
“BIOPAS is the leader in commercializing CNS therapies in Latin America and we are delighted to announce these agreements to make INBRIJA available there to people with Parkinson’s disease who suffer from OFF periods,” M.D., president and CEO of Acorda Therapeutics, Ron Cohen, said in the release. “We are also in active discussions with other companies for the rights to commercialize INBRIJA in additional countries.”